TerminatedPhase 3NCT04934670

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Xenikos
Principal Investigator: Mary Horowitz, MD, MS, MD, MPH
Center for International Blood and Marrow Transplant Research
Intervention: T-Guard(drug)
Enrollment: 12 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2023

Study locations (30)

University of Alabama, Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Washington University St. Louis, St Louis, Missouri, United States
Mount Sinai Medical Center, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Wake Forest University, Winston-Salem, North Carolina, United States
Ohio State University, Columbus, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Utah, Salt Lake City, Utah, United States
University of Wisconsin, Madison, Wisconsin, United States
Site BE300, Brussels, Belgium
Site BE301, Brussels, Belgium
Site BE307, Ghent, Belgium
+15 more locations on ClinicalTrials.gov

Collaborators

National Heart, Lung, and Blood Institute (NHLBI) · Blood and Marrow Transplant Clinical Trials Network · National Cancer Institute (NCI) · National Marrow Donor Program

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04934670 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease →

← Back to all trials